Clinical trials
Urinary Bladder Neoplasms trials in Austria
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
31 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 2 |
| 2002 | 1 |
| 2005 | 2 |
| 2007 | 1 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 1 |
| 2015 | 1 |
| 2017 | 1 |
| 2018 | 3 |
| 2019 | 2 |
| 2020 | 3 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 2 |
| 2025 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 21 |
| Active, not recruiting | 4 |
| Recruiting | 3 |
| Terminated | 2 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Bristol-Myers Squibb | 5 |
| European Organisation for Research and Treatment of Cancer - EORTC | 3 |
| AstraZeneca | 2 |
| David D'Andrea | 2 |
| Photocure | 2 |
| Amgen | 1 |
| Arbeitsgemeinschaft medikamentoese Tumortherapie | 1 |
| Astellas Pharma Global Development, Inc. | 1 |
| Barmherzige Brüder Vienna | 1 |
| Basilea Pharmaceutica | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Urinary Bladder Neoplasms | 31 |
| Carcinoma, Transitional Cell | 7 |
| Lung Neoplasms | 6 |
| Neoplasms | 4 |
| Breast Neoplasms | 3 |
| Kidney Neoplasms | 3 |
| Non-Muscle Invasive Bladder Neoplasms | 3 |
| Ovarian Neoplasms | 3 |
| Pancreatic Neoplasms | 3 |
| Biliary Tract Neoplasms | 2 |
Trials
Showing 1 to 25 of 31. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.